Results 71 to 80 of about 10,352 (222)

Friend or Foe? Eosinophilic Granulomatosis with Polyangiitis (EGPA) Onset After Dupilumab: Report of Two Cases and a Narrative Review of the Literature

Rheumato
Background/Objectives: Dupilumab is a fully human IgG4 monoclonal antibody targeting the interleukin-4 receptor α subunit, inhibiting interleukin-4 and interleukin-13 signalling, and suppressing type 2 inflammation.
Alessia Gatti, Giulia Fontana, Jacopo Mora, Franco Franceschini, Ilaria Cavazzana, Paola Toniati, Francesca Regola   +6 more
doaj   +1 more source

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando, Giuseppe Licci, Marella Reale, Veronica Seccia, Alessia Giorli, Paolo Iannicelli, Dario Zaccari, Valentina Rossi, Jacopo Cambi, Stefano Berrettini, Marco Mandalà, Gianluca Leopardi, Antonio Sarno, Luca Muscatello, Simone Bocuzzi, Franco Trabalzini, Giandomenico Maggiore, Oreste Gallo   +17 more
wiley   +1 more source

Characterization of Prurigo Nodules in Adults With Moderate‐To‐Severe Atopic Dermatitis in Japan: A 2‐Year Observational Study

The Journal of Dermatology, EarlyView.
ABSTRACT Clinical phenotypes of atopic dermatitis (AD) can vary, with some individuals displaying difficult‐to‐treat prurigo nodularis‐like lesions. We aimed to assess the real‐world disease burden and treatment course of Japanese adults with AD‐associated prurigo nodules (AD‐Pn) receiving conventional AD treatments.
Yoko Kataoka, Takafumi Etoh, Hidehisa Saeki, Norito Katoh, Satoshi Teramukai, Yuki Tajima, Kwinten Bosman, Marius Ardeleanu, Kazuhiko Arima   +8 more
wiley   +1 more source

Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study

The Journal of Dermatology, EarlyView.
ABSTRACT This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or ...
Ryo Saito, Wataru Sasaki, Haruka Watanabe, Momoka Hashimoto, Rina Kamigaki, Kento Nagiri, Akio Tanaka   +6 more
wiley   +1 more source

Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case–Control Study

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory skin disease in which dupilumab, an interleukin‐4 receptor alpha antagonist, has become a cornerstone therapy for moderate‐to‐severe disease. However, persistent facial and neck erythema and related symptoms have been increasingly reported during dupilumab treatment, and the underlying ...
Pinar Dursun, Ayse Nur Saribas Yildirim, Ayca Yazici   +2 more
wiley   +1 more source

Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae

International Medical Case Reports Journal, 2020
Filippos Vingopoulos, Douglas R Lazzaro New York University School of Medicine, Department of Ophthalmology, New York, NY 10017, USACorrespondence: Douglas R LazzaroNew York University School of Medicine, Department of Ophthalmology, 222 East 41st Street,
Vingopoulos F, Lazzaro DR
doaj  

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual‐Center Study

The Journal of Dermatology, EarlyView.
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Ruggero Cascio Ingurgio, Angela Alfano, Aalia Syed, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Dedee F. Murrell   +6 more
wiley   +1 more source

Differential Effects of Dupilumab in a Patient With Localized Heat Urticaria, Delayed Solar Urticaria, and Symptomatic Dermographism

The Journal of Dermatology, EarlyView.
ABSTRACT Physical urticaria is a subtype of chronic inducible urticaria characterized by wheals and/or angioedema triggered by physical stimuli. We report a refractory case of combined localized heat urticaria, delayed solar urticaria, and symptomatic dermographism in a 16‐year‐old girl.
Shuta Yoshitani, Shinichi Moriwaki, Atsushi Fukunaga   +2 more
wiley   +1 more source

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach

Clinical Case Reports
The off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source